NNovo Nordisk Read More Is its obesity drug dominance strong enough to sustain long-t2026-04-21 With blockbuster drugs like Ozempic driving massive growth, you need to know if Novo Nordisk’s leadership in diabetes…
NNovo Nordisk Read More Is its obesity drug dominance strong enough to sustain long-t2026-04-21 With blockbuster drugs like Wegovy driving massive growth, you need to know if Novo Nordisk’s lead in the…
NNovo Nordisk Read More Novo Nordisk’s etavopivat hits phase 3 goals in SCD | NVO SEC Filing2026-04-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT…
NNovo Nordisk Read More The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust2026-04-15 Key Points Eli Lilly has a stronger weight-loss portfolio than Novo Nordisk. Eli Lilly also has a deep…
NNovo Nordisk Read More Novo Nordisk updates DKK 15B share buyback | NVO SEC Filing2026-04-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT…
NNovo Nordisk Read More Novo Nordisk AGM approves 2025 dividend, buyback | NVO SEC Filing2026-03-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT…
NNovo Nordisk Read More Novo Nordisk wins FDA approval for Awiqli insulin | NVO SEC Filing2026-03-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT…
NNovo Nordisk Read More Novo Nordisk updates 2026 share bu… | NVO SEC Filing2026-03-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT…
NNovo Nordisk Read More Novo Nordisk wins FDA approval for Wegovy HD | NVO SEC Filing2026-03-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT…
NNovo Nordisk Read More Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?2026-03-20 Key Points Novo Nordisk unveiled a troubling guidance for 2026, which tanked the stock. It recently reached a…
NNovo Nordisk Read More Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?2026-03-20 Key Points Novo Nordisk unveiled a troubling guidance for 2026, which tanked the stock. It recently reached a…
NNovo Nordisk Read More Novo Nordisk Receives FDA Approval For Higher Dose Of Its Weight-Loss Drug Wegovy2026-03-19 The company stated that Wegovy HD received the FDA’s accelerated approval based on results from the STEP UP…